AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Preconditioned Human Mesenchymal Stem Cells (hMSCs) for Musculoskeletal Tissue Repair

Technology Benefits
Improved cell survival and engraftment Able to manipulate biophysical properties of spheroid-hydrogel system
Technology Application
Bone repair Orthopedic and plastic surgery Tissue repair
Detailed Technology Description
Bone defects that extend beyond a critical size are associated with impaired native healing due to age or disease. Approximately 10% of patients with bone defects do not have sufficient bone repair processes, leading to fractures, infections, and other comorbidities. Human mesenchymal stem cell (hMSC)-based therapies have high therapeutic potential for such bone repair but have limited efficacy in vivo: calcification of surrounding tissue occurs due to limited oxygen supply and decreased nutrient exchange. Researchers at the University of California, Davis have developed a novel treatment for bone repair that offers an optimized survival rate of human mesenchymal stem cells and engraftment once implanted into a bone defect. The method incorporates pre-treatment of the cells combined with an engineered cell carrier system, resulting in synergistically improved bone healing compared to existing monolayer cell therapies and spheroid formation methods. This method has successfully exhibited higher cell density, osteogenic potential and increased secretion of proangiogenic factors in vitro with significantly more bone healing in critical-sized femoral segment defects in rats in vivo. This method represents a simple approach for enhanced, long-term therapeutic bone healing.
Others

Tech ID/UC Case

29121/2018-293-0


Related Cases

2018-293-0

*Abstract

Researchers at the University of California, Davis have developed a preconditioning treatment and delivery method for human mesenchymal stem cell (hMSC) for enhanced bone healing.

*Principal Investigator

Name: Steve Ho

Department:


Name: Kent Leach

Department:

Country/Region
USA

For more information, please click Here
Mobile Device